Correlation of Bcl-2 expression with prognosis and survival in patients with head and neck cancer: A systematic review and meta-analysis

Silva, Fábio França Vieira e; Caponio, Vito Carlo Alberto; Camolesi, Gisela Cristina Vianna; Padín-Iruegas, María Elena; Lorenzo-Pouso, Alejandro I.; Lima, Karine Cassano; Vieira, Sérgio Lannes; Chamorro-Petronacci, Cintia; Suárez-Peñaranda, José Manuel; Pérez‐Sayáns, Mario

doi:10.1016/j.critrevonc.2023.104021

Cited by 7 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bcl-2 is initially identified as an oncogene in cases of human follicular B-cell lymphoma with a t(14;18) chromosome translocation [146,147]. It has also been linked to various types of tumors such as lung cancer, breast cancer, gastric cancer, non-small cell lung cancer, and head and neck cancer [148][149][150][151][152]. Our results showed no association between Bcl-2 expression and recurrence of meningioma patients.…”

Section: Plos Onementioning

confidence: 43%

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

Aung,

Ngamjarus,

Proungvitaya

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. This study aims to evaluate the prognostic value of immunohistochemistry-based (IHC) biomarkers of meningioma patients. A systematic literature search was conducted up to November 2023 on PubMed, CENTRAL, CINAHL Plus, and Scopus databases. Two authors independently reviewed the identified relevant studies, extracted data, and assessed the risk of bias of the studies included. Meta-analyses were performed with the hazard ratio (HR) and 95% confidence interval (CI) of overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS). The risk of bias in the included studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool. A total of 100 studies with 16,745 patients were included in this review. As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II α (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). Although only in single studies, KPNA2, CDK6, Cox-2, MCM7 and PCNA are proposed as additional markers with high expression that are related with poor prognosis of meningioma patients. In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.

show abstract

Section: Plos Onementioning

confidence: 43%

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

Aung,

Ngamjarus,

Proungvitaya

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Bcl-2 is a key mitochondrial protein that regulates apoptosis, with overexpression of the protein neutralizing pro-apoptotic proteins and inhibiting apoptosis [157]. In HNC, the role of Bcl-2 as a prognostic and predictive biomarker remains equivocal, with conflicting evidence.…”

Section: Bcl-2mentioning

confidence: 99%

“…In HNC, the role of Bcl-2 as a prognostic and predictive biomarker remains equivocal, with conflicting evidence. Several studies have found Bcl-2 overexpression to be an independent risk factor for HNC [158,159], as well as an independent poor prognostic factor [157,160]. However, others have contrarily reported that a negative Bcl-2 expression correlates with a worse prognosis [161,162] or indicated no association between Bcl-2 expression and prognosis or tumor aggressiveness [162][163][164].…”

Section: Bcl-2mentioning

confidence: 99%

Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

Eberly,

Sciscent,

Lorenz

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Head and neck cancers (HNC) are a biologically diverse set of cancers that are responsible for over 660,000 new diagnoses each year. Current therapies for HNC require a comprehensive, multimodal approach encompassing resection, radiation therapy, and systemic therapy. With an increased understanding of the mechanisms behind HNC, there has been growing interest in more accurate prognostic indicators of disease, effective post-treatment surveillance, and individualized treatments. This chapter will highlight the commonly used and studied biomarkers in head and neck squamous cell carcinoma.

show abstract

“…Tumors were predominantly located on the tongue, representing 44.6% (37) of cases, followed by 30.1% (25) in masticatory mucosa and 25.3% (21) on the oor of the mouth. Biopsies were mainly incisional, representing 71% (59) rather than excisional in 29% (24). In the tumors majority, 84.3% (70) were ulcerated, and 15.7% (13) were nonulcerated.…”

Section: Sample Descriptionmentioning

confidence: 99%

“…Its overexpression is commonly associated with increased sensitivity to immunotherapy, radiotherapy, and/or chemotherapy, and consequently serves as an important prognostic predictor [11]. Furthermore, Smac/DIABLO has become an important target in the development of medications that aim to use the mechanism of action to overcome apoptotic evasion through increased expression of pro-apoptotic action proteins, preventing the proliferation of cancer cells [22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Pro-apoptotic Smac/DIABLO Acts as an Independent Prognostic Factor in Oral Squamous Cell Carcinoma

Silva,

Padín-Iruegas,

Caponio

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Oral squamous cell carcinoma (OSCC) poses significant health risks with increasing incidence and mortality rates. In this context, there is an urgent need to explore novel biomarkers to enhance therapeutic strategies and improve survival. Understanding apoptotic evasion in cancer pathogenesis, this pioneering study aims to investigate the correlation between a pro-apoptotic protein Smac/DIABLO and patient prognosis within the OSCC cohort. Methodology: Immunohistochemistry was employed to analyze Smac/DIABLO expression and correlate with clinicopathological and prognostic factors during a long-term follow-up. Results Smac/DIABLO low expression was associated with worse overall survival (OS), relapse-free survival (RFS), disease-specific survival (DSS), and an increase in risk of lymph node metastasis (LNM) in univariate analyses. Furthermore, multivariate analyses confirmed Smac/DIABLO as an independent prognostic factor, predicting poorer OS, RFS, DSS, and increased likelihood of LNM. Patients with positive Smac/DIABLO expression exhibited three times higher survival probability. Conclusion Low proapoptotic protein Smac/DIABLO expression significantly influences prognostic predictions and strongly correlates with poor OSCC outcomes. Enhancing Smac/DIABLO protein expression via Smac/DIABLO mimetic compounds can represent a key point in anti-cancer therapy targeting OSCC.

show abstract

Correlation of Bcl-2 expression with prognosis and survival in patients with head and neck cancer: A systematic review and meta-analysis

Cited by 7 publications

References 46 publications

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

Pro-apoptotic Smac/DIABLO Acts as an Independent Prognostic Factor in Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About